Identification of fibroblast growth factor 1 (FGF-1) in a black market product

Drug Testing and Analysis

Volumn 3, Issue 11-12, 2011, Pages 791-797

  Walpurgis, Katja ^a   Thomas, Andreas ^a   Laussmann, Tim ^b   Horta, Luis ^c   Metzger, Sabine ^d   Schänzer, Wilhelm ^a   Thevis, Mario ^a  

^a GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^b Centre for Education and Science of the Federal Revenue Administration   (Germany)

^c Av Prof Egas Moniz   (Portugal)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Doping; Growth factors; Mass spectrometry; Sport

Indexed keywords

BODY FLUIDS; CELL CULTURE; ELECTROPHORESIS; FIBROBLASTS; HEALTH RISKS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MUSCLE; SPORTS; TISSUE REGENERATION;

BLACK MARKET; CLINICAL TRIAL; FIBROBLAST GROWTH FACTOR-1; GROWTH FACTOR; MARKET PRODUCTS; ONE-DIMENSIONAL; PERFORMANCE ENHANCING; SPORTS INJURIES; TWO-DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS; WORLD ANTI-DOPING AGENCY;

PROTEINS;

RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 1; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; ATHLETE; DISEASE ASSOCIATION; HIGH RESOLUTION ORBITRAP MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN MODIFICATION; TISSUE REGENERATION;

EID: 84855237232     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.364     Document Type: Article

References (23)

1. Y.R. Yun, J.E. Won, E. Jeon, S. Lee, W. Kang, H. Jo, J.H. Jang, U.S. Shin, H.W. Kim Fibroblast growth factors: biology, function, and application for tissue regeneration. J. Tissue Eng. 2010, 2010, 218142.
2. D.M. Ornitz, N. Itoh Fibroblast growth factors. Genome Biol. 2001, 2, Reviews 3005.
3. M. Zakrzewska, E. Marcinkowska, A. Wiedlocha FGF-1: from biology through engineering to potential medical applications. Crit. Rev. Clin. Lab. Sci. 2008, 45, 91.
4. B. Thisse, C. Thisse Functions and regulations of fibroblast growth factor signaling during embryonic development. Dev. Biol. 2005, 287, 390.
5. L. Hutley, W. Shurety, F. Newell, R. McGeary, N. Pelton, J. Grant, A. Herington, D. Cameron, J. Whitehead, J. Prins Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes 2004, 53, 3097.
6. M. Zakrzewska, D. Krowarsch, A. Wiedlocha, J. Otlewski Design of fully active FGF-1 variants with increased stability. Protein Eng. Des. Sel. 2004, 17, 603.
7. J.F. Culajay, S.I. Blaber, A. Khurana, M. Blaber Thermodynamic characterization of mutants of human fibroblast growth factor 1 with an increased physiological half-life. Biochemistry 2000, 39, 7153.
8. S. Nikol, I. Baumgartner, E. Van Belle, et al. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol. Ther. 2008, 16, 972.
9. American Heart Association. 2010 clinical trial/clinical science abstracts. Circulation 2010, 122, 2215.
10. WADA. Prohibited List 2011. Available at: [December 2010].
11. L. Creaney, B. Hamilton Growth factor delivery methods in the management of sports injuries: the state of play. Brit. J. Sports Med. 2008, 42, 314.
12. 2010 Prohibited List - Summary of Major Modifications. Availale at: [April 2011].
13. A. Thomas, M. Kohler, J. Mester, H. Geyer, W. Schänzer, M. Petrou, M. Thevis Identification of the growth-hormone-releasing peptide-2 (GHRP-2) in a nutritional supplement. Drug Test. Analysis 2010, 2, 144.
14. M. Kohler, A. Thomas, K. Walpurgis, K. Terlouw, W. Schänzer, M. Thevis Detection of His-tagged Long-R(3)-IGF-I in a black market product. Growth Horm. IGF Res. 2010, 20, 386.
15. M. Kohler, A. Thomas, H. Geyer, M. Petrou, W. Schänzer, M. Thevis Confiscated black market products and nutritional supplements with non-approved ingredients analyzed in the cologne doping control laboratory. Drug Test. Analysis 2010, 2, 533-537.
16. M. Thevis, A. Thomas, M. Kohler, S. Beuck, W. Schänzer Emerging drugs: mechanism of action, mass spectrometry and doping control analysis. J. Mass Spectrom. 2009, 44, 442.
17. WADA. Technical Document - TD2010IDCR. Available at: [June 2011].
18. M. Thevis, Mass Spectrometry in Sports Drug Testing - Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons, New Jersey, 2010.
19. M. Zakrzewska, A. Wiedlocha, A. Szlachcic, D. Krowarsch, J. Otlewski, S. Olsnes Increased protein stability of FGF1 can compensate for its reduced affinity for heparin. J. Biol. Chem. 2009, 284, 25388.
20. ExPASy Proteomics Server. Available at: [March 2011].
21. Universal Protein Resource (UniProt). Available at: [March 2011].
22. Serum Cellular Repair - not just another anti-aging product. Available at: [March 2011].
23. Dermatropin. Available at: [March 2011].